T2	location 495 499	U.S.
T3	total-participants 518 522	9939
T4	age 534 548	50 to 79 years
T5	eligibility 549 602	with prior hysterectomy and known oophorectomy status
T6	intervention 604 637	Conjugated equine estrogens (CEE)
T7	control 654 661	placebo
T10	outcome 2039 2054	adverse effects
T11	outcome 1484 1516	reduction in all-cause mortality
T12	outcome 1197 1215	net adverse effect
T1	outcome-Measure 729 751	invasive breast cancer
T8	outcome-Measure 689 724	Incidence of coronary heart disease
T9	outcome-Measure 788 807	all-cause mortality
T13	outcome-Measure 815 829	"global index"
